anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Reduced preload and thoracic blood volume accompany postural tachycardia syndrome (POTS). Head-down tilt (HDT) increases both preload and intrathoracic blood volume. The objective of this study was to assess the safety and efficacy of HDT in POTS in acute settings.
METHODS: This retrospective study evaluated POTS patients. Analyzed data included heart rate, blood pressure, cerebral blood flow velocity (CBFv) in the middle cerebral artery, and capnography. The baseline supine hemodynamic data were compared with the data obtained at the second minute of the -10° HDT. A linear mixed-effects model was used to assess the effect of HDT on hemodynamic variables.
RESULTS: The HDT was explored in seven POTS patients and an additional seven POTS patients without HDT served as controls. In the HDT arm, four POTS patients had overlapping diagnoses of myalgic encephalopathy/chronic fatigue syndrome (ME/CFS) and one patient had comorbidity of post-acute sequelae of SARS-CoV-2 infection (PASC). HDT lowered heart rate by 10% and increased end-tidal CO2 by 8%. There was no change in other cardiovascular variables.
CONCLUSIONS: In the acute setting, HDT is safe. HDT reduces the heart rate presumably by modulating baroreflex by enhancing preload and stroke volume, which in turn increases thoracic blood volume with a net effect of parasympathetic cardiovagal activation and/or sympathetic withdrawal. This pilot study provides a foundation to proceed with longitudinal studies exploring the long-term effect of repetitive HDT in conditions associated with preload failure such as POTS, ME/CSF, and PASC.
The invention discloses wolfberry-containing health hericium erinaceus rice wine and a preparation method thereof. The wolfberry-containing health hericium erinaceus rice wine is prepared from 30-35 parts by weight of hericium erinaceus, 300-320 parts by weight of rice, 2-3 parts by weight of pine nut, 3-4 parts by weight of roasted sweet potato, 2-3 parts by weight of chicken kidney powder, 1-2 parts by weight of rose petal, 10-12 parts by weight of wolfberry juice, 1-2 parts by weight of sea-buckthorn, 1-2 parts by weight of gynostemma pentaphylla, 1-2 parts by weight of wapiti embryo, 2-3 parts by weight of scallion, 2-3 parts by weight of ginger, 2-4 parts by weight of cooking wine and a proper amount of distiller's yeast, yeast, table salt and water. The preparation method comprises chopping rose petals, immersing the chopped rose petals in a wolfberry juice, putting pine nuts into the wolfberry juice, carrying out heating boiling, and adding roasted sweet potato and chicken kidney powder into the mixture. The rose petal improves a powder delicate fragrance. The wolfberry juice improves powder health effects and has a thick fragrance and a good taste. The used traditional Chinese medicines have effects of diminishing inflammation and removing toxins, and relieving cough and removing phlegm. The hericium erinaceus is immersed in rice washing water with table salt and the rice washing water is natural alkaline water so that a hericium erinaceus bitter taste is reduced well.
Psilocybin with psychological support: Psilocybin will be administered in the form of capsules, taken orally with water. Each participant will receive 2 doses, approximately 4 weeks apart.
PURPOSE:To obtain the subject composition, containing an extract separated from a leaf of Eriobotrya japonica Lindl. with a hydrophilic organic solvent, a sodium alkyl sulfate or sucrose ester of a fatty acid or further an extract from a fruit or a seed of Hovenia dulcis Thunb. with the hydrophilic organic solvent and capable of inhibiting formation of bacterial plaques. CONSTITUTION:A composition for the oral cavity, containing an extract separated from a leaf of Eriobotrya japonica Lindl. with a hydrophilic organic solvent, excellent in inhibitory effects on formation of bacterial plaques causing carious teeth and useful for dentifrices, foods, etc. A sodium alkyl sulfate or sucrose ester of a fatty acid or further an extract from a fruit or a seed of Hovenia dulcis Thunb. with the hydrophilic organic solvent is combined with the aforementioned composition to afford an excellent composition for the oral cavity capable of exhibiting sufficient preventive effects on the carious teeth even at a low concentration of the extract from the leaf of the Eriobotrya japonica Lindl. The above-mentioned composition has inhibitory activity against adhesion of Streptococcus mutans to tooth surfaces and glucosyltransferase of the Streptococcus mutans c type (CA-GTase) and is capable of inhibiting formation of the cavity hygiene.
This is a randomized, open-label, three-arm study. The participants will be enrolled and randomized in a ratio of 1:1:1 to receive 5.0g, 7.5g, 10g b.i.d. of MZRW at 9 am respectively. The study drug, MZRW will be administrated to the participants by site personnel after participants have fasted overnight for more than 8 hours and 6 hours after administration. Each participant will consume a standardized meal. In addition, the participants refrain from Semen Cannabis Sativae, Semen Pruni Armeniacae, Radix Paeoniae, Fructus Immaturus Citri Aurantii, Cortex Magnoliae and Radix et Rhizoma Rhei foods for 3 days before the study until completion of the study.

Blood samples (5 ml each) will be collected from the medial cubital vein into evacuated tubes containing heparin just before and at 0.25, 0.5, 1, 2, 4, 8, 12h after administration and were immediately centrifuged (1700g, 10 min). Plasma fractions were stored at -20°C until analysis. All study procedures conduct in accordance with the ethical principles of the Declaration of Helsinki, consistent with Good Clinical Practice guidelines, and approved by Hong Kong Baptist University Ethics Committee on the Use of Human Subjects for Teaching and Research. Subjects will be given their written informed consent before participating in the study. Urine samples (50 ml each) will be collected the day before the administration and at 0 to 3h, 3 to 6h, 6 to 9h and 9 to 12h after administration. Plasma and urine fractions will be stored at -80°C until analysis.
Triptolide acrylate, and its preparation method and application are provided. The invention discloses a novel triptolide derivative, which is shown in a formula I. The invention also discloses a preparation method of the compound and medical application of the compound in preparing anti-cancer drugs. The triptolide acrylate and the pharmaceutically acceptable salt thereof have anticancer activity, and animal in vivo experiments can effectively inhibit the tumor growth of animals. A plurality of in vitro experiments prove that the protein expression quantity of p53 can be obviously increased, the apoptosis of tumor cells is promoted, the growth of the tumor cells is effectively inhibited, and the function of inhibiting the metastasis of cancer cells is achieved. More importantly, the toxicity to normal cells is less than that of triptolide.
This is an open-label, phase 1b trial of ADI-PEG 20 in combination with pembrolizumab in subjects with advanced cancers. Dose escalation will occur using a 3 + 3 + 3 design.

The first subject in a dose escalation cohort must have had treatment with ADI-PEG 20 + pembrolizumab with a week of follow up) before the next 2 subjects are enrolled. Thus subjects 2 and 3 may be enrolled on day 8 if there is no dose limiting toxicity (DLT) in subject 1. No additional delay is required between treating subjects 4 to 6 or 7 to 9 in an expanded cohort. Before proceeding to the next cohort dose level, the first 3 eligible subjects in each cohort will have received at least 21 days of treatment (i.e. at least 2 of the expected 3 doses of ADI-PEG 20 + one dose of pembrolizumab).
An automatic medical coding system is provided. The system parses features of natural language diagnosis and procedure information. The features are compared to elements of a medical coding system. Medical codes corresponding to medical coding system elements that match features of the diagnosis and procedure information are mapped to the received diagnosis and procedure information. The mapped medical code is assigned a score reflecting the estimated reliability of the mapped medical code based on the amount of manipulation of the received diagnosis and procedure information leading to the match. The scored medical code may be submitted to a workflow making use of medical codes. The scored medical code may optionally be presented to a user for review prior to further utilization of the scored medical code.
INTRODUCTION: Muscle strengthening training (MST) and behavioural graded activity (BGA) show comparable effects on knee osteoarthritic (KOA) pain, but the mechanisms of action remain unclear. Both exercise-induced anti-inflammation and central sensitisation are promising pathways for pain relief in response to exercise therapy in patients with KOA: MST has the potential to decrease inflammation and BGA has the potential to decrease central sensitisation. Hence, this study aims to examine inflammation and central sensitisation as mediators for the effect of MST and/or BGA on pain in patients with KOA.
METHODS AND ANALYSIS: The Knee OsteoArthritis PAIN trial started on 10 January 2020 (anticipated end: April 2024). The three-arm clinical trial aims to recruit 90 KOA patients who will be randomly allocated to 12 weeks of (1) MST, (2) BGA or (3) care as usual. Assessments will be performed at baseline, 13 and 52 weeks after finishing the intervention. Outcomes, including pain (Knee injury and Osteoarthritis Outcome Score), were chosen in line with the OARSI recommendations for clinical trials of rehabilitation interventions for OA and the IMMPACT/OMERACT recommendations for the assessment of physical function in chronic pain clinical trials. Inflammation as well as features of central sensitisation (including conditioned pain modulation, offset analgesia, temporal summation of pain and event-related potentials following electrical stimulation), will be considered as treatment mediators. A multiple mediators model will be estimated with a path-analysis using structural equation models. In July 2023, all 90 KOA patients have been included and 42 participants already finished the study.
ETHICS AND DISSEMINATION: This study obtained ethics approval (B.U.N. 143201941843). Unravelling the mechanisms of action of exercise therapy in KOA will not only be extremely valuable for researchers, but also for exercise immunology and pain scientists and clinicians.
TRIAL REGISTRATION NUMBER: NCT04362618.
A unit dose sachet containing a pharmaceutical formulation of Ibuprofen (400mg) or a pharmaceutically acceptable salt thereof. Preferred salts of Ibuprofen include the Lysine and sodium salts. An additional active ingredient selected from paracetamol, guaifenesin, cetyl pyridinium chloride and phenylephrine HCl may be present. The pharmaceutical formulation may be in the form of a liquid, a powder, granules or pellets. In another aspect, a process for the preparation of the unit dose sachet comprising the steps of a) preparing the pharmaceutical formulation, b) introducing the pharmaceutical formulation into a sachet and c) sealing the sachet. In yet another aspect, the use of said unit dose sachet as a General Sales List medicament. The unit dose sachet may be useful in the treatment of fever, colds, influenza, arthritis, primary dysmenorrhoea, pain including rheumatic and muscular pain, sprains, strains, backache, neuralgia, migraine, headache, toothache, menstrual pain, Alzheimer's disease and Parkinson's disease.
Participants in Phase 1 that was not responsive will continue on to the Phase 2 of the study. Positive response is defined as a decrease of blood phenylalanine of 30% or greater from baseline taken from morning blood serum. The Phase 2 component of the study will be a 2 week period of dietary restriction.
Stress (emotional, physical, social) facilitates drug seeking behavior through the activation of the HPA axis, autonomic nervous system, and brain DA systems. Furthermore, alterations within several neuropeptide systems (CRF, Substance P, and others) also contribute to the role of stress in addiction. Central to this project is that anxiety and stress responses are modulated by substance P and its preferred target, the NK1 receptor. Therefore the aim of this pilot clinical trial is to determine the safety and efficacy of aprepitant (a neurokinin 1 (NK1) receptor antagonist). We hypothesize that the NK1 receptor antagonist, aprepitant, will be safe, tolerable and efficacious at reducing the withdrawal symptoms, cue craving, and reinforcement value for both cannabis and tobacco resulting from the cessation of either or both drugs. We will assess this hypothesis in the context of a carefully controlled human laboratory study in which subjects (N=72) will be randomized in a 3 x 2 factorial design to one of 3 behavioral conditions; a) withdrawn from both substances, b) withdrawn from tobacco only, or c) withdrawn from cannabis only, and to receive one of 2 medication dose conditions: placebo or aprepitant (160 mg/day). Medication will be administered for 5 days, followed by a cue challenge, choice procedure, and then a consequence (i.e., oral cannabis or a cigarette or money) also on day 5.
The vast number of theoretically conceivable compounds resulting from the combination of all claimed substituents in formula (I) precludes a comprehensive search. For economical reasons the search has been limited to the following compounds: R1 is a hydrocarbon radical unsubstituted or substituted by only one OH-group and having a linear chain of at least 8 carbons atoms(A); the NR2R3 group is either a linear alpha-, beta-, or gamma-, amino acid (e.g. amino acids like proline are not included), or a glycosamine residue. Despite the above limitation the search revealed too many relevant compounds. Therefore the search was further limited to compounds with NR2R3 = Glycine, beta-Alamine, gamma-amino-butyric acid, Serine- or Cysteine derivatives, or glycosamine of the following structures: (a), (b), (c). Still too many pertinent compounds where retrieved which can not all be cited in the search report. The documents cited are only an arbitrary selection and the search report has to be regarded as incomplete.
Stroke as a cerebrovascular accident has a significant prevalence, as well it was addressed a one of major etiologies for other comorbidities, even mortality. Where, cardiac rehabilitation is a structured exercise program that almost designed to offer an opportunity to break the inactivity cycle, reduce associated cardiovascular risks, also improve perceived confidence and quality of life in stroke survivors . Therefore, aerobic training could be defined as a core component that focuses on cardio-respiratory fitness, walking speed and endurance for stroke survivors. Up on that, this clinical trial will be conducted to investigate the effect of aerobic training on cardiorespiratory fitness and health related quality of life in stroke survivors. It will be conducted on eighty post stroke patient (hemiplegic; 55-65 years old with functional ambulatory category more than 3) from Outpatient clinic of neurological department of El-Kasr El-Aini Hospital. They will be allocated into 2 groups; Group A will involves 40 patients will receive aerobic training program, plus traditional physical therapy program. While, Group B will involves 40 patients will receive traditional physical therapy program only. 6-Menutes walk test, Stroke impact scale are the outcome measures.
Participants with moderate renal insufficiency will receive a single dose of 4 mg/kg sugammadex administered as an IV bolus over 10 seconds. Dose will be administered into a peripheral vein through an IV catheter connected to an IV tubing with injection port. The IV tubing is connected to a saline bag. Free-flowing access to the vein will be confirmed immediately prior to dose administration, and dose will be followed by saline flush.
The present invention relates to methods and additives for increasing active agent elution control coatings and 'elution control coatings including the same. In an embodiment the invention includes an elution control coating comprising a polymeric matrix and at least about 0.1 wt. % of an additive dispersed in the polymeric matrix. The additive can include polyvinylpyrrolidone or a copolymer thereof. An active agent can be dispersed within the polymeric matrix, the active agent having limited solubility in water. Embodiments of the invention also include a method of forming an elution control coating comprising estradiol, ployethylene-co-vinyl acetate copolymer (PEVA), poly-n-butylmethacrylate (PBMA) and polyvinylpyrrolidone (PVP).
Usual care as described for the CG will also be provided to the IG. Wound healing measurement, therapeutic adherence measurement, wound recurrence measurement, and questionnaires will be provided by the institute's nurses. After baseline data collection (T0) and random allocation to the intervention group, this usual care will be enhanced by frequenting a social leg program.
Induction retention enema for the first week of treatment followed by once weekly administration of 15 capsules of study treatment (the equivalent of 7.5 grams of human stool) will be (administered within 60 minutes of thawing once weekly) for 7 weeks. After completing 8 weeks of blinded study treatment, study subjects on FMT who have shown improvement will be given the option to receive open-label maintenance FMT weekly for an additional 8 weeks of once weekly FMT capsule administration.
Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

The safety and efficacy of oxybutynin chloride extended-release tablets were evaluated in a total of 580 participants who received oxybutynin chloride extended-release tablets in 4 clinical trials (429 patients) and four pharmacokinetic studies (151 healthy volunteers). The 429 patients were treated with 5 - 30 mg/day for up to 4.5 months. Three of the 4 clinical trials allowed dose adjustments based on efficacy and adverse events and one was a fixed-dose escalation design. Safety information is provided for 429 patients from these three controlled clinical studies and one open-label study in the first column of Table 2 below.

Adverse reactions from two additional fixed-dose, activecontrolled, 12-week treatment duration, postmarketing studies, in which 576 patients were treated with oxybutynin chloride extended-release tablets 10 mg/day, are also listed in Table 2 (second column).

The most common adverse reactions reported by the 429 patients receiving 5 - 30 mg/day oxybutynin chloride extended-release tablets were the expected side effects of anticholinergic agents. The incidence of dry mouth was dose-related.

The discontinuation rate for all adverse reactions was 6.8% in the 429 patients from the 4 studies of efficacy and safety who received 5-30 mg/day. The most frequent adverse reactions causing early discontinuation of study medication was nausea (1.9%), while discontinuation due to dry mouth was 1.2%.

In addition, the following adverse reactions were reported by ≥ 1 to < 5% of all patients who received oxybutynin chloride extended-release tablets in the 6 adjustable and fixed-dose efficacy and safety studies. Psychiatric disorders: depression, nervousness, insomnia, confusional state; Nervous System Disorders: dysgeusia; Cardiac disorders: palpitations; Vascular disorders: hypertension; Respiratory, thoracic and mediastinal disorders: nasal dryness, cough, oropharyngeal pain, dry throat; Gastrointestinal Disorders: gastroesophageal reflux disease, abdominal pain, flatulence, vomiting; Skin and subcutaneous tissue disorders: dry skin, pruritus; Renal and urinary disorders: urinary retention, urinary hesitation, dysuria; General disorders and administration site conditions: fatigue, edema peripheral, chest pain.

The following adverse reactions were reported by <1% of oxybutynin chloride extended-release tablets-treated patients and at a higher incidence than placebo in clinical trials: Metabolism and Nutrition Disorders: anorexia, fluid retention; Vascular disorders: hot flush; Respiratory, thoracic and mediastinal disorders: dysphonia; Gastrointestinal Disorders: dysphagia, frequent bowel movements; General disorders and administration site conditions: chest discomfort, thirst.
Age 18-65; female and male. No methotrexate or statin therapy in prior 3 months. Not on biological therapies. Fulfill 1982 ACR revised criteria for SLE. SLE activity status designated using the SLEDAI disease activity index. Patients excluded if previous documentation of a connective tissue disorder other than SLE.
Part B-Arm 1 will include approximately 20 patients with gastric cancer (including gastric esophageal junction). This subject group will receive RC118-ADC and Toripalimab (3.0mg/kg) Day 1 of every 14-day cycle. The starting dose of RC118-ADC for expansion will be derived from the RP2D determined during Part A.
A 70-year-old male presented with diplopia and painless proptosis of the left eye for 5 months. Examination showed 6 mm of axial proptosis and restriction of supraduction, abduction and adduction, and mild limitation of infraduction of the left eye. Magnetic resonance imaging demonstrated a large, moderately well-circumscribed intraconal mass in the left lateral orbit, and excisional biopsy was performed. Histopathologic features of mixed fibrous and myxoid areas in a whorl-like pattern and immunohistochemical staining for MUC4 confirmed the diagnosis of low-grade fibromyxoid sarcoma (LGFMS). Next-generation sequencing revealed genetic fusion of EWSR1-CREB3L1. LGFMS is an extremely rare neoplasm with only two prior documented cases of orbital involvement. Here, we report the third case of orbital LGFMS.
Composition (A) for treatment and prevention of bone tumors and metastases that preferentially colonize bone tissue comprises as active agent killed or weakly pathogenic microorganisms that contain a gene for bone sialoprotein (BSP) and can express one or more BSP. The expressed BSP differ from endogenous human BSP of normal osteoblasts in at least one structural feature so that an immune reaction against the altered BSP is generated. ACTIVITY : Cytostatic. No details of tests for cytostatic activity are given. MECHANISM OF ACTION : Vaccine; induction of an immune response against abnormal BSP expressed by tumor cells. Immunization against abnormal BSP protects against attachment of metastatic osteotrophic cells from the primary tumor and induces cell-mediated cytotoxicity against cells that produce the abnormal BSP.
All enrolled patients will undergo a baseline 18F-FDG PET scan as part of their standard clinical treatment for NSCLC. Dynamic 18F-FMISO PET scans will be performed on one of the GE PET/CT scanners in 3D mode, at least one day after the baseline 18F-FDG PET scan. The dynamic baseline 18F-FMISO studies may precede the 18F-FDG study if the patient had a CT or PET/CT scan within the last 30 days that would permit the investigators to localize the tumor of interest during the 18F-FMISO study. In a group of 5 patients, the feasibility of simultaneous imaging of 18F-FMISO and 18F-FDG will be assessed. The patient will have an IV line placed for radiotracer injection and for venous blood sampling. All dynamic PET scans will be performed over one PET FOV centered at the lesion position. The 18F-FDG mid-treatment PET/CT scan will be performed over only one bed position.